Cargando…

Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease

INTRODUCTION: The use of antipsychotic medications in Alzheimer's disease has been associated with an increased risk of mortality in clinical trials. However, an older postmortem literature suggests that those with schizophrenia treated in an era of exclusively conventional antipsychotic medica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koppel, Jeremy, Jimenez, Heidy, Adrien, Leslie, Greenwald, Blaine S., Marambaud, Philippe, Cinamon, Ezra, Davies, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644277/ https://www.ncbi.nlm.nih.gov/pubmed/29067299 http://dx.doi.org/10.1016/j.trci.2016.05.003

Ejemplares similares

The Impact of Muscarinic Antagonism on Psychosis-Relevant Behaviors and Striatal [(11)C] Raclopride Binding in Tau Mouse Models of Alzheimer’s Disease
por: Jimenez, Heidy, et al.
Publicado: (2023)

Anesthesia promotes acute expression of genes related to Alzheimer’s disease and latent tau aggregation in transgenic mouse models of tauopathy
por: Eun, John David, et al.
Publicado: (2022)

The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT– and rTg(P301L)4510 mouse models of Alzheimer's disease
por: Jimenez, Heidy, et al.
Publicado: (2022)

AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
por: Domise, Manon, et al.
Publicado: (2016)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice
por: Davidowitz, Eliot J., et al.
Publicado: (2023)

Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions
por: Koppel, Jeremy, et al.
Publicado: (2014)

A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis
por: Beckman, Danielle, et al.
Publicado: (2021)

Trans‐seeding of Alzheimer‐related tau protein by a yeast prion
por: Flach, Martin, et al.
Publicado: (2022)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology
por: Hou, Xu, et al.
Publicado: (2020)

Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease
por: Picard, Cynthia, et al.
Publicado: (2021)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice
por: Davidowitz, Eliot J., et al.
Publicado: (2020)

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022)

Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease
por: Yu, Chao-Chao, et al.
Publicado: (2019)

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
por: Rawat, Priyanka, et al.
Publicado: (2022)

Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau
por: Rosenqvist, Nina, et al.
Publicado: (2018)

Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease
por: Lau, Dawn H. W., et al.
Publicado: (2016)

PKR kinase directly regulates tau expression and Alzheimer's disease‐related tau phosphorylation
por: Reimer, Lasse, et al.
Publicado: (2020)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
por: Zhou, Yan, et al.
Publicado: (2018)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates
por: Datta, Dibyadeep, et al.
Publicado: (2021)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Phosphorylation of different tau sites during progression of Alzheimer’s disease
por: Neddens, Joerg, et al.
Publicado: (2018)

CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation
por: Shim, Kyu Hwan, et al.
Publicado: (2020)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

In-Cell NMR Study of Tau and MARK2 Phosphorylated Tau
por: Zhang, Shengnan, et al.
Publicado: (2018)

Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models
por: Vitale, Francesca, et al.
Publicado: (2020)

NPT088 reduces both amyloid-β and tau pathologies in transgenic mice
por: Levenson, Jonathan M., et al.
Publicado: (2016)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

The Evolution of Tau Phosphorylation and Interactions
por: Trushina, Nataliya I., et al.
Publicado: (2019)

Loss of Axonal Mitochondria Promotes Tau-Mediated Neurodegeneration and Alzheimer's Disease–Related Tau Phosphorylation Via PAR-1
por: Iijima-Ando, Kanae, et al.
Publicado: (2012)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qpn2tigdg5tq5dn706g2h1ie61